Company Description
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Dr. Daniel Vitt Ph.D. |
Contact Details
Address: 1200 Avenue Of The Americas, Suite 200 New York, X1 10036 X1 | |
| Phone | (332) 255-9818 |
| Website | immunic-therapeutics.com |
Stock Details
| Ticker Symbol | IMUX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001280776 |
| CUSIP Number | 4525EP101 |
| ISIN Number | US4525EP1011 |
| Employer ID | 56-2358443 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Vitt Ph.D. | Chief Executive Officer, President and Director |
| Dr. Duane D. Nash J.D., M.B.A., M.D. | Executive Chairman |
| Glenn Whaley CPA | Chief Financial Officer |
| Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer |
| Dr. Hella Kohlhof | Chief Scientific Officer |
| Jessica Breu | Head of Investor Relations and Communications |
| Inderpal Singh | General Counsel |
| Patrick Walsh | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 424B5 | Filing |
| May 31, 2024 | EFFECT | Notice of Effectiveness |
| May 24, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 30, 2024 | EFFECT | Notice of Effectiveness |
| Apr 30, 2024 | 424B3 | Prospectus |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |